Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet
inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients
undergoing coronary stenting. Although in this setting the potent oral P2Y12 inhibitor
prasugrel is commonly utilized, there is very limited data on the optimal approach for
switching between these therapies. The overarching aim of this investigation is to rule out a
drug drug interaction (DDI) when cangrelor and prasugrel are concomitantly administered in
patients undergoing coronary stenting.
Phase:
Phase 4
Details
Lead Sponsor:
University of Florida
Collaborators:
Scott R MacKenzie Foundation Scott R. MacKenzie Foundation